• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Acelyrin Inc (NQ: SLRN )

    3.945 -0.035 (-0.88%)
    Streaming Delayed Price Updated: 10:26 AM EDT, Aug 16, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 649,717
    Open 3.850
    Bid (Size) 3.940 (3)
    Ask (Size) 3.950 (10)
    Prev. Close 3.980
    Today's Range 3.850 - 4.030
    52wk Range 3.360 - 29.88
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
    Acelyrin reports promising Phase 3 results for izokibep in hidradenitis suppurativa, announces a strategic focus on lonigutamab. 
    Via Benzinga
    Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -50.31%
    -50.31%
    1 Month
    -44.12%
    -44.12%
    3 Month
    -14.79%
    -14.79%
    6 Month
    -47.61%
    -47.61%
    1 Year
    -85.37%
    -85.37%

    More News

    Read More
    SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
    Via InvestorPlace
    ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
    From ACELYRIN, INC.
    Via GlobeNewswire
    SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
    Via InvestorPlace
    SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
    Via InvestorPlace
    Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Announces Leadership Transition
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
    From ACELYRIN, INC.
    Via GlobeNewswire
    Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
    From Avalo Therapeutics
    Via GlobeNewswire
    Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
    Via Benzinga
    ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
    From ACELYRIN, INC.
    Via GlobeNewswire
    Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
    Via Benzinga
    ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
    From ACELYRIN, INC.
    Via GlobeNewswire
    Acelyrin (SLRN) Investor Update: Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    SLRN DEADLINE TOMORROW: ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    SLRN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.